* If you want to update the article please login/register
Introduction Hepatitis B surface antigen clearance is the treatment objective for hepatitis B e antigen-negative patients with chronic hepatitis B. This research was conducted to determine the peginterferon alfa-2b's safety in NAs-experienced patients with CHB with negative HBeAg and low HBsAg levels. Methods HBeAg-negative patients with CHB who received NAs treatment for over 24 weeks had HBsAg 1500 IU/mL and HBV DNA 100 IU/mL, with HBsAg 1500 IU/mL and HBV DNA 100 IU/mL, were enrolled. HBV DNA was undetectable in serum HBV blood samples from week 48 of all PegIFN-2b add-on therapy patients, according to the fourth week. At week 48, only patients with PegIFN-2b add-on therapy and HBsAg seroconversion achieved HBsAg clearance and HBsAg seroconversion. Patients with baseline HBsAg clearance rate and HBsAg seroconversion rate at week 48 were among the highest HBsAg clearance rate and HBsAg seroconversion rate. After 48 weeks of therapy, HBsAg clearance and seroconversion at week 72 had no significant difference between continuing or discontinuing PegIFN-2b therapy.
Source link: https://doi.org/10.1007/s40121-021-00497-5
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions